Skip to main content
L

LTR PHARMA LIMITED — Investor Relations & Filings

Ticker · LTP ISIN · AU0000305294 ASX Manufacturing
Filings indexed 127 across all filing types
Latest filing 2026-04-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX LTP

About LTR PHARMA LIMITED

https://ltrpharma.com

LTR Pharma Limited focuses on the development and commercialization of innovative therapies for men’s health. The company’s lead product candidate, SPONTAN, is a proprietary nasal spray formulation of vardenafil designed for the treatment of erectile dysfunction. Utilizing a unique delivery platform, SPONTAN is engineered to provide a significantly faster onset of action compared to traditional oral medications. By leveraging advanced drug delivery technology to bypass first-pass metabolism, the formulation aims to improve patient outcomes and reduce the time to efficacy. LTR Pharma is dedicated to advancing its clinical programs through regulatory pathways to provide rapid-acting solutions for men’s health conditions.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 392.1KB
Interim / Quarterly Report Q3 2026
2026-04-27 English
Investor Presentation 22 pages 2.4MB
Regulatory Filings
2026-03-10 English
SPONTAN Phase II Clinical Study Completes Recruitment 2 pages 152.1KB
Regulatory Filings
2026-03-04 English
Appendix 4D and Half Yearly Report 38 pages 12.4MB
Regulatory Filings
2026-02-25 English
Application for quotation of securities - LTP 6 pages 18.5KB
Regulatory Filings
2026-02-09 English
SPONTAN Shows Positive Outcomes in Younger Men with ED 3 pages 470.3KB
Regulatory Filings
2026-02-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.